Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016', provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects - The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Overview 11 Therapeutics Development 12 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Stage of Development 12 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Therapy Area 13 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Indication 14 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Companies 17 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Products under Development by Universities/Institutes 21 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Companies Involved in Therapeutics Development 29 Ablynx NV 29 Agilvax Inc 30 Aridis Pharmaceuticals LLC 31 Aviragen Therapeutics Inc 32 Bavarian Nordic A/S 33 Celltrion, Inc. 34 Emergent BioSolutions Inc. 35 F. Hoffmann-La Roche Ltd. 36 Gene Techno Science Co., Ltd. 37 GenVec, Inc. 38 Gilead Sciences, Inc. 39 GlaxoSmithKline Plc 40 iBio, Inc. 41 Johnson & Johnson 42 mAbxience S.A. 43 MedImmune LLC 44 Medivir AB 45 Mucosis B.V. 46 Navigen Pharmaceuticals, Inc. 47 NeuClone Pty Ltd 48 Novavax, Inc. 49 Regeneron Pharmaceuticals Inc 50 Takeda Pharmaceutical Company Limited 51 TechnoVax, Inc. 52 The International Biotechnology Center (IBC) Generium 53 Vaxart Inc 54 VBI Vaccines Inc 55 VLP Biotech, Inc. 56 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Drug Profiles 57 (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 AK-0529 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ALX-0171 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 AR-201 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 AX-14 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 BTA-585 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 CR-32T - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 DT-preF - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 GNR-007 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 GV-2311 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 JNJ-61187165AAA - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 JNJ-61187191AAA - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 JNJ-64400141 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 MEDI-7510 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 MEDI-8897 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 MVA-RSV - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 palivizumab biosimilar - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 palivizumab biosimilar - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 palivizumab biosimilar - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 palivizumab biosimilar - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 palivizumab biosimilar - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 palivizumab biosimilar - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 presatovir - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 respiratory syncytial virus (virus like particle) vaccines - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 respiratory syncytial virus immune globulin (human) - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 respiratory syncytial virus vaccine - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 respiratory syncytial virus vaccine - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 respiratory syncytial virus vaccine - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 respiratory syncytial virus vaccine - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 respiratory syncytial virus vaccine - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 respiratory syncytial virus vaccine - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 respiratory syncytial virus vaccine - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 respiratory syncytial virus vaccine - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 RSV-001 - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 RV-521 - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 suptavumab - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 SynGEM - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Dormant Projects 121 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Discontinued Products 122 Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Featured News & Press Releases 123 Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus 123 Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 123 Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 124 Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 124 Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults 125 Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126 Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 126 Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine 127 Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine 127 Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 128 May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections 129 May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 129 May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 130 May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalized with a RSV infection 131 Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections 132 Appendix 133 Methodology 133 Coverage 133 Secondary Research 133 Primary Research 133 Expert Panel Validation 133 Contact Us 133 Disclaimer 134
List of Tables
Number of Products under Development for, H2 2016 12 Number of Products under Development by Therapy Area, H2 2016 13 Number of Products under Development by Indication, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Pipeline by Ablynx NV, H2 2016 29 Pipeline by Agilvax Inc, H2 2016 30 Pipeline by Aridis Pharmaceuticals LLC, H2 2016 31 Pipeline by Aviragen Therapeutics Inc, H2 2016 32 Pipeline by Bavarian Nordic A/S, H2 2016 33 Pipeline by Celltrion, Inc., H2 2016 34 Pipeline by Emergent BioSolutions Inc., H2 2016 35 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36 Pipeline by Gene Techno Science Co., Ltd., H2 2016 37 Pipeline by GenVec, Inc., H2 2016 38 Pipeline by Gilead Sciences, Inc., H2 2016 39 Pipeline by GlaxoSmithKline Plc, H2 2016 40 Pipeline by iBio, Inc., H2 2016 41 Pipeline by Johnson & Johnson, H2 2016 42 Pipeline by mAbxience S.A., H2 2016 43 Pipeline by MedImmune LLC, H2 2016 44 Pipeline by Medivir AB, H2 2016 45 Pipeline by Mucosis B.V., H2 2016 46 Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 47 Pipeline by NeuClone Pty Ltd, H2 2016 48 Pipeline by Novavax, Inc., H2 2016 49 Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 50 Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 51 Pipeline by TechnoVax, Inc., H2 2016 52 Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 53 Pipeline by Vaxart Inc, H2 2016 54 Pipeline by VBI Vaccines Inc, H2 2016 55 Pipeline by VLP Biotech, Inc., H2 2016 56 Dormant Projects, H2 2016 121 Discontinued Products, H2 2016 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
